DexCom And Companion Medical Collaboration To Support CGM
Zacks Investment Research | Jun 07, 2019 08:26AM ET
DexCom, Inc. (NASDAQ:DXCM) recently collaborated with Companion Medical to enable a direct exchange of CGM (Continuous Glucose Monitoring) data from InPen into both the companies’ software applications. The latest development is likely to pave the way for advanced diabetes decision support apart from fortifying DexCom’s foothold in the CGM space.
Notably, as part of this alliance, Dexcom and Companion Medical will help InPen users display long-acting and rapid-acting insulin data in the Dexcom CLARITY Diabetes Management Software.
For investors’ notice, Companion Medical is a developer of advanced technology to improve diabetes care. The company’s flagship product InPen is the first and only FDA-cleared smart insulin pen which enables constant tracking and monitoring of blood glucose levels.
Other Tie-Ups
DexCom has collaborative agreements with several companies, which should not only bring in cash in the form of milestone payments and royalties but should also help expand its product use.
In recent times, DexCom acquired TypeZero Technologies and expects to launch the first automated insulin delivery system using TypeZero's InControl algorithm by 2019. DexCom also has agreements with companies like Tandem Diabetes Care, Animas Corp (a subsidiary of Johnson & Johnson (NYSE:JNJ)) and Edward Lifesciences (NYSE:EW) for the development and commercialization of products utilizing its technologies.
Market Prospects
Diabetes is one of the most challenging health conditions in the United States. About 1.4 million new cases of diabetes are diagnosed every year in the country, thanks to the rise in geriatric population, urbanization and poor lifestyle practices.
Going by an article of Research and Markets, the blood glucose monitoring devices market is expected to witness a CAGR of more than 9% till 2024.
Price Performance
Over the past year, this Zacks Rank #2 (Buy) stock has rallied 29.8% against the industry ’s 3.8% decline.
Other Key Picks
Other top-ranked stocks in the broader medical space are Cerner Corporation (NASDAQ:CERN) and Penumbra (NYSE:PEN) . While Cerner sports a Zacks Rank #1 (Strong Buy), Penumbra has a Zacks Rank #2.
Cerner’s long-term earnings growth rate is expected to be 13.5%.
Penumbra’s long-term earnings growth rate is projected at 21.5%.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple (NASDAQ:AAPL) sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Get The News You Want
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.